Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
    • Transcripts
    • AGM Invitations
    • IPOs
  • inderesTV
  • Portfolio
  • Forum
  • Discovery
  • Premium
  • Femme
  • Nora AI
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team
Log in to your Inderes Free account to see all free content on this page.
Create account

CellaVision

151.00 SEK

-2.08 %

1,476 following

CEVI

NASDAQ Stockholm

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
-2.08 %
-0.53 %
-3.94 %
-3.94 %
-15.26 %
-11.28 %
-18.38 %
-53.31 %
+867.95 %

CellaVision operates in the medical technology industry and focuses on the development and manufacture of systems for digital blood analysis. The company focuses on digital cell morphology and offers innovations for analyzers, instruments, reagents and software used in hematology laboratories. The company's products are aimed at healthcare institutions and laboratories worldwide. CellaVision was founded in 1994 and is headquartered in Lund, Sweden.

Read more
Market cap
3.6B SEK
Turnover
1.22M SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
24.4.
2026

Interim report Q1'26

28.4.
2026

General meeting '26

29.4.
2026

Annual dividend

All
Webcasts
Press releases
ShowingAll content types
CellaVision, Audiocast, Q1'26
Webcast4/24/2026, 9:00 AM

CellaVision, Audiocast, Q1'26

CellaVision
Regulatory press release4/1/2026, 6:20 AM

CellaVision publishes its 2025 Annual and Sustainability Report

CellaVision
Regulatory press release3/25/2026, 7:00 AM

NOTICE OF ANNUAL GENERAL MEETING IN CELLAVISION AB (publ)

CellaVision

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
Create account
Press release3/11/2026, 7:20 AM

The new CellaVision® Bone Marrow Aspirate Application launches in EMEA

CellaVision
CellaVision, Audiocast, Q4'25
Webcast2/5/2026, 10:00 AM

CellaVision, Audiocast, Q4'25

CellaVision
Regulatory press release2/5/2026, 6:20 AM

Solid Quarter driven by Strong Performance in Americas

CellaVision
Press release2/2/2026, 2:00 PM

Modular Finance IR Consensus: CellaVision – Consensus estimates Q4 2025

CellaVision
Press release1/22/2026, 7:20 AM

Invitation to Presentation of the CellaVision Year-end Report 2025 on February 5, at 11:00 CET

CellaVision
Regulatory press release12/12/2025, 2:00 PM

CellaVision appoints Monica Jönsson as new CFO

CellaVision
Regulatory press release12/8/2025, 6:20 AM

CellaVision receives CE marking according to IVDR Class C for CellaVision® Bone Marrow Aspirate Application

CellaVision
CellaVision, Audiocast, Q3'25
Webcast11/6/2025, 10:00 AM

CellaVision, Audiocast, Q3'25

CellaVision
Regulatory press release11/6/2025, 6:20 AM

Softer Quarter with Mixed Regional Performance

CellaVision
Press release11/3/2025, 2:00 PM

Modular Finance IR Consensus: CellaVision – Consensus estimates Q3 2025

CellaVision
Press release10/23/2025, 6:20 AM

Invitation to Presentation of the CellaVision Report for the Third Quarter 2025 on November 6, at 11:00 CET

CellaVision
Regulatory press release10/21/2025, 6:20 AM

Nomination Committee for the CellaVision Annual General Meeting 2026

CellaVision
Regulatory press release9/2/2025, 8:15 AM

CellaVision appoints Monica Jönsson as Interim CFO

CellaVision
Press release7/22/2025, 6:27 AM

Redeye: Cellavision Q2 2025 - Stable with Decent Growth

CellaVision
CellaVision, Audiocast, Q2'25
Webcast7/18/2025, 9:00 AM

CellaVision, Audiocast, Q2'25

CellaVision
Regulatory press release7/18/2025, 5:20 AM

Robust Result with Mixed Regional Performance

CellaVision
Press release7/15/2025, 1:30 PM

Modular Finance IR Consensus: CellaVision – Consensus estimates Q2 2025

CellaVision
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.